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Abstract: CRISPR/Cas9 is an emerging gene editing tool. This technology, which evolved naturally as a defense mechanism for bacteria 
and other prokaryotes, has been repurposed to edit genes in a wide array of cells, including human cells. This paper outlines the discovery, 
mechanism, and potential applications of CRISPR/Cas9. 
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ost physical harm arises in three ways: injuries, infections, 
and genetic diseases. For the most part, injuries and infec-
tions are well understood and treatments well established. 
Genetic diseases are more difficult to understand, and treat-
ments usually target the symptoms, not the cause of the disease. 
Prevention revolves around removing environmental contribu-
tors to the disease, but it fails to address the genetic aspect of 
the disease. Finding effective ways to treat and prevent genetic 
diseases is the last puzzle piece in ensuring physical wellness. 
While there are many emerging genetic therapies, one of the 
most promising is the gene editing CRISPR/Cas9 technology.1 
What are CRISPR and Cas9? In 1987, researchers stud-
ying the bacteria E. coli noticed short repeated segments in the 
bacteria’s DNA. The repeated segments were grouped near each 
other on the bacteria’s chromosome separated by unique DNA 
sequences called spacers.2 This group of repeated segments and 
spacers is called Clustered Regularly Interspaced Short Palin-
dromic Repeats (CRISPR). In addition to the short repeats and 
spacers, there are other genes and proteins that work with 
CRISPR. The other genes and proteins that work with CRISPR are 
said to be CRISPR-associated (Cas). Since its discovery in 1987,3 
CRISPR has been identified in around 50% of bacteria.4 In 2005, 
it was noticed that these unique spacers matched foreign DNA 
fragments from viruses and plasmids that infect bacteria. It was 
predicted that CRISPR could possibly be a way for bacteria to 
protect themselves from foreign DNA.5 In 2008, it was proven 
that CRISPR could provide protection from foreign DNA.3 
The way CRISPR provides protection for bacteria can be 
summarized into three phases: adaption, biogenesis, and inter-
ference. In the adaptation phase, foreign DNA enters the bacte-
ria, and a part of this DNA, known as the protospacer, is cut out 
and added to the CRISPR region of the bacteria’s chromosome 
as a new spacer.6 This process allows the bacteria to keep a rec-
ord of the viruses or other foreign DNA by which it has been 
infected. The way CRISPR integrates these new spacers into the 
genome or selects the protospacer from the rest of the foreign 
DNA is known for some bacteria and unknown for others.7 The 
biogenesis phase occurs when the portion of this foreign ge-
nome that was previously stored as a spacer in the CRISPR re-
gion is copied into CRISPR RNA (crRNA). The last phase, inter-
ference, occurs when a Cas protein uses the crRNA as a template 
to match the foreign DNA.6 The outcome following the crRNA 
and DNA match is dependent upon which Cas protein was uti-
lized. For example, Cas3 cuts and degrades single stranded DNA; 
Cas10 degrades both DNA and RNA; and Cas9 cuts double 
stranded DNA.6 By cutting and degrading the foreign genome, 
CRISPR effectively protects the bacteria from recurring infec-
tions. 
It is clear CRISPR can help bacteria survive, but how can 
employing this system be useful in humans? Interestingly, the 
same mechanisms the bacteria use to prevent infections can also 
be used to cut other sequences of DNA, including human DNA. 
By changing the crRNA guide template associated with the Cas9 
protein, it could be possible to edit any gene in the human 
body!5 CRISPR/Cas9 refers to the use of crRNA and the Cas9 pro-
tein to edit genes. CRISPR/Cas9 as a gene editing tool works al-
most in the same way as CRISPR interference. The Cas9 protein, 
with the help of a guide crRNA sequence, binds and cuts double 
stranded DNA.8 However, instead of degrading the DNA like 
CRISPR interference in bacteria cells, human cells attempt to re-
pair the damaged DNA. The cell can utilize two different repair 
pathways: non-homologous end joining and homology-directed 
repair. Non-homologous end joining (NHEJ) does not always re-
join the cut DNA perfectly, and that can often result in a mutated 
gene.6 While normally a gene mutation would be detrimental, it 
could be useful in gene editing to selectively turn off an unwant-
ed gene.9 Homology-directed repair (HDR) does not reattach the 
broken DNA; instead it inserts new DNA into the break that is 
homologous, or similar, to the original sequence. When HDR 
takes place, there is the possibility a new gene will be inserted 
into the genome.10 This activity can replace non-functional 
genes with functional genes. 
It is also possible to use CRISPR/Cas9 to affect gene 
expression without cutting the DNA. This process requires a 
Cas9 protein that can bind to the DNA but lacks cutting ability.6 
The mutated Cas9 remains on the DNA and makes transcription 
of the gene more difficult. Transcription is an important step in 
expressing genes, so by making it more difficult, the expression 
of this gene is reduced and even silenced in some genes.11 Mu-
tated Cas9 proteins can also bind to silencers, which are places 
that reduce gene expression. When bound, Cas9 proteins pre-
vent the action of silencers and increase transcription of a certain 
gene.12 Ideally, CRISPR/Cas9 could be used to replace or remove 
any gene and increase or decrease any gene’s expression. 
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However, problems may occur in the body when using 
CRISPR/Cas9. Off-target mutations are one concern associated 
with CRISPR/Cas9 use.13 The Cas9 protein may cut the DNA 
somewhere other than its intended target, which can cause an 
unwanted and potentially harmful mutation. Another problem is 
delivering the Cas9 protein and the guide crRNA into the cells.14 
However, CRISPR/Cas9 is a new technology, and new systems 
are being developed to overcome these challenges. Synthetic 
CRISPR RNA (scrRNA) uses chemically modified nucleotides to 
work around the delivery problem while also managing to 
increase cleavage activity and decrease off-site mutations.15 De-
spite the achievements of new CRISPR/Cas9 systems, their ap-
plication and use still raise concerns. Until CRISPR/Cas9 is better 
understood, parts of the scientific community are requesting 
moratorium on all studies that would use CRISPR/Cas9 to alter 
cells that pass genes on to children.16 Studies that use 
CRISPR/Cas9 to edit cells that do not pass genetic information 
on to children are still being conducted. 
One developing area of research for CRIPSR/Cas9 is 
cancer treatment. Cancer is a disease that affects millions of peo-
ple around the world. One approach for cancer treatment is to 
fix tumor suppressor genes.16 In a cancer cell, tumor suppressor 
genes are mutated. CRISPR/Cas9 has been used successfully to 
activate multiple tumor suppressor genes in bladder cancer cells. 
These activated tumor suppressor genes were shown to induce 
apoptosis or cell death, inhibit growth, and inhibit metastasis of 
the bladder cancer cells.17 CRISPR/Cas9 was also used to knock-
out the CDK11 gene, which promotes cancer cell proliferation in 
bone cancer. Silencing the CDK11 gene led to a decrease in bone 
cancer cell growth, and even induced apoptosis for some bone 
cancers.18 Treating and preventing cancer with CRISPR/Cas9 is 
an exciting new field that will hopefully expand in the near fu-
ture. 
Another potential application for CRIPSR/Cas9 is the 
treatment and prevention of human acquired immunodeficiency 
syndrome (AIDS). AIDS is the result of an infection from the hu-
man immunodeficiency virus (HIV). CRISPR/Cas9 can be used to 
treat AIDS in multiple ways. One way is to attack and cut out 
latent viruses that have incorporated into the host cells genome. 
The virus most often targets Helper T cells, where it integrates 
its own genome into the host cell.19 CRISPR/Cas9 is being used 
to program the crRNA guide for the Cas9 protein so it matches 
up with the latent viral DNA in the Helper T cell. When the 
CRISPR/Cas9 system is in the Helper T cell, it cuts and mutates 
the latent viral DNA, so the virus can no longer replicate and 
infect other cells.20 This kind of treatment is called a “sterilizing 
cure” because it rids the body of all of the viruses, even latent 
strands. There are also “functional cures” where the latent virus 
is still present, but new infections are prevented.21 Research is 
being conducted on a “functional cure” that mutates a receptor 
HIV needs for binding to the Helper T Cells.19 CRISPR/Cas9 can 
be used to mutate this CCR5 receptor to a naturally occurring 
mutated version, CCRΔ32, that is resistant to HIV infections.22 
Although the use of CRISPR/Cas9 for treatment and prevention 
of HIV/AIDS is in its early stages, it looks promising and could 
potentially cure a devastating disease. 
It is possible that the different applications of the 
CRISPR/Cas9 system will see growth in the coming years. Inter-
est in CRISPR/Cas9 has only increased since its discovery, and 
the favorable study results in treating HIV and cancer hopefully 
increase interest in these areas. Successfully treating and pre-
venting diseases by addressing the genetic aspect via 
CRISPR/Cas9 therapy could help to complete the puzzle and im-
prove physical wellness for people across the globe.  
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